Khavinson Bioregulators

The Khavinson bioregulator catalog is a uniquely Russian contribution to peptide pharmacology — a series of synthetic ultrashort peptides (typically 2-4 amino acids) developed since the 1970s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The catalog now includes 20+ entries we cover in this directory: Epitalon (KEDG, pineal), Cortagen (AEDG/AEDP, cortex), Pinealon (EDR, pineal), Vilon (KE, immune), Thymalin (calf-thymus extract, immune), Thymulin (zinc thymulin, thymic), Thymagen (KE-related, thymic), Cardiogen (AEDR, heart), Bronchogen (AEDL, lung), Prostamax (KEDP, prostate), Testagen (KEDG, testes), Pancragen (KEDW, pancreas), Cartalax (AEDG, cartilage), Livagen (KEDW, liver), Chonluten (EDG, lung mucosa), Ovagen (EDL, ovaries), Vesugen (KED, vasculature), Vesilute (vascular), Crystagen (EDP, thymus), and N-acetyl-epitalon-amidate (a stabilized epitalon variant).

The core Khavinson framework proposes that these short peptides act as tissue-specific epigenetic regulators that bind directly to DNA, modulate chromatin structure, and selectively regulate gene expression in tissue-specific ways — a mechanism the group has elaborated in extensive Russian peer-reviewed publications and in some Western-indexed work. The framework is supported by a real Russian clinical and preclinical literature spanning four decades, but the mechanistic claims (particularly the direct peptide-DNA binding hypothesis) have not been validated to the standards of mainstream molecular biology, where claims of sequence-specific peptide-DNA interaction would require structural-biology characterization that has not been performed for the catalog. The honest framing is that the Khavinson program has produced a substantial body of work in Russian-tradition gerontology and tissue-bioregulator pharmacology, but it sits outside Western evidence-based clinical practice — none of the catalog entries have FDA, EMA, UK MHRA, or other major-jurisdiction approval as therapeutics.

This page is the family-level pillar covering the Khavinson catalog as a whole. For individual peptide pages with full evidence ratings, dosing, and references, follow the links to each member below.

Shared mechanism

The Khavinson framework proposes that the catalog peptides act as tissue-specific epigenetic regulators of gene expression, binding directly to DNA and modulating chromatin structure to selectively activate or repress genes in target tissues. The mechanism, as articulated in the Khavinson group's reviews (most extensively in Khavinson 2012 Bull Exp Biol Med, PMID 22803113, and Khavinson 2022 IJMS, PMID 35887081), centers on three claims: (1) the short peptides reach intracellular targets despite their small size and rapid plasma degradation, via POT (proton-coupled oligopeptide transporter) and LAT (large amino acid transporter) family members on cell membranes; (2) once inside cells, the peptides bind DNA at specific sequences with selectivity that produces tissue-typical gene-regulation effects; and (3) the resulting gene-expression changes account for the tissue-specific phenotypic effects observed in animal and clinical studies.

The individual catalog entries are positioned as having tissue-targeted activity matching the original natural-extract preparation they were derived from: Vilon (KE) and Thymalin (calf-thymus extract) for thymic and immune function, Cortagen (AEDP/AEDG) and Pinealon (EDR) for cortex and pineal, Epitalon (KEDG) for pineal/aging, Cardiogen (AEDR) for heart, Bronchogen (AEDL) and Chonluten (EDG) for lung, Prostamax (KEDP) for prostate, Testagen (KEDG) for testes, Ovagen (EDL) for ovaries, Pancragen (KEDW) for pancreas, Cartalax (AEDG) for cartilage, Livagen (KEDW) for liver, Vesugen (KED) and Vesilute for vasculature, Crystagen (EDP) for thymus, and Thymagen (KE-related) for thymus.

Specific reported effects include: Epitalon's induction of telomerase activity in human somatic cells (Khavinson 2003, PMID 12937682) and overcoming of the Hayflick division limit (Khavinson 2004, PMID 15455129); Vilon and related peptides' effects on monocyte/macrophage proliferation and inflammatory pathways (Avolio 2022, PMID 35408963); Thymalin-derived peptide effects on COVID-19-relevant gene expression (Linkova 2023, PMID 37686182); thymocyte blast transformation and sphingomyelin signaling in response to the catalog more broadly (Khavinson 2002, PMID 12420072).

From a Western pharmacological perspective, the principal mechanistic concerns are: (1) tripeptides and dipeptides have very short plasma half-lives (typically minutes), poor blood-brain-barrier penetration, and rapid degradation by aminopeptidases, dipeptidyl peptidases, and other peptidases — making sustained intracellular concentrations sufficient for gene-regulation effects mechanistically demanding; (2) the proposed direct peptide-DNA binding mechanism with sequence-specific selectivity has not been characterized at structural resolution (X-ray crystallography or cryo-EM of peptide-DNA complexes), leaving the molecular basis of the proposed selectivity unsupported; (3) independent Western replication of the mechanistic claims is limited; and (4) the in-vivo pharmacokinetics of the catalog peptides in humans are largely uncharacterized in PubMed-indexed work. These concerns do not invalidate the broader observational and clinical literature from the Khavinson group, but they are the reasons the framework has not been adopted into Western evidence-based clinical practice.

History & discovery

The Khavinson bioregulator program began in the 1970s under Vladimir Khavinson and Vyacheslav Morozov at what is now the St. Petersburg Institute of Bioregulation and Gerontology. The original focus was on natural-extract polypeptide preparations derived from animal tissues — Thymalin (calf thymus, late 1970s), Epithalamin (pineal gland), Cortexin (cerebral cortex), Prostatilen (prostate), and others. These 'cytomedins' were complex peptide mixtures used in Soviet and post-Soviet Russian clinical practice for age-related and tissue-specific dysfunction — the natural-extract preparations have substantial Russian clinical experience accumulated over decades, with primarily Russian-language documentation.

The synthetic short-peptide catalog (the 'cytogens' or 'biogenic peptides') emerged from the late 1980s and 1990s as Khavinson's group attempted to identify the active components of the natural-extract preparations and reproduce their effects with synthetic alternatives of defined structure. The synthetic catalog grew through systematic screening to include dipeptides, tripeptides, and tetrapeptides — most prominently KE (Vilon, immune), AEDG (Epitalon, pineal), KEDP (Prostamax, prostate), and the broader catalog now spanning 20+ entries.

Key scientific milestones in the Khavinson framework include the 2003 Bull Exp Biol Med paper from Khavinson and colleagues showing that Epitalon (KEDG) induced telomerase activity and telomere elongation in human somatic cells (PMID 12937682) — a result that drew international attention because telomerase activation in somatic cells is a non-trivial finding. The 2004 follow-up (PMID 15455129) reported that the peptide promoted overcoming the Hayflick division limit. Subsequent work characterized effects of catalog entries on thymocyte signaling (Khavinson 2002, PMID 12420072), epigenetic regulation more broadly (Khavinson 2012, PMID 22803113), and proposed transport mechanisms via POT (proton-coupled oligopeptide transporters) and LAT (large amino acid transporters) (Khavinson 2022 IJMS, PMID 35887081) addressing the question of how short peptides reach intracellular targets given rapid plasma degradation.

Independent Western recognition of the program has been mixed. Morozov and Khavinson's 1997 Int J Immunopharmacol review (PMID 9637345) framed the natural and synthetic thymic peptide approach for an English-language audience. Avolio and colleagues (IJMS 2022, PMID 35408963) characterized Vilon-class peptides in monocyte/macrophage cell-line models. Linkova and colleagues (IJMS 2023, PMID 37686182) studied Thymalin-derived peptides in COVID-19-relevant gene expression. The Western-indexed footprint is real but small relative to the broader Russian literature, and the mechanistic claims have not been replicated to mainstream molecular-biology standards. Notably, the Khavinson laboratory's claim of direct peptide-DNA binding with sequence-specific gene regulation would require X-ray crystallography or cryo-EM structures of peptide-DNA complexes that have not been published for the catalog.

The contemporary status (2026) is that the Khavinson catalog is widely available through Russian-market dietary peptide complexes (Peptides.ru, Khavinson Peptides product line) and through Western research-channel and grey-market peptide vendors. None of the catalog entries are FDA-approved or registered as Western prescription medicines. The fitness, anti-aging, and longevity communities engage with the catalog at a level somewhere between mainstream pharmaceutical use and traditional/alternative medicine. The honest framing is that the Khavinson program is a real Russian peptide-pharmacology tradition with substantial peer-reviewed depth in Russian-language venues, but it is not Western evidence-based clinical practice and should not be conflated with FDA-approved peptide therapeutics.

State of evidence

Evidence in this family is asymmetric across the catalog. The natural-extract preparations (Thymalin, Epithalamin, Cortexin, Prostatilen) have substantial Russian clinical experience accumulated over decades, primarily documented in Russian-language sources. The synthetic chemically-defined catalog entries have variable peer-reviewed footprints — Epitalon (KEDG) is the best-supported with multiple PubMed-indexed papers including the foundational telomerase-induction work (Khavinson 2003), Vilon (KE) has extensive Russian and some Western-indexed coverage, and the broader catalog spans from substantial coverage (Cortagen, Pinealon) to thin coverage (Testagen, Crystagen, Vesilute) where Russian-language work dominates and Western indexing is sparse.

No Khavinson catalog entry has FDA approval, EMA approval, UK MHRA approval, or registration as a Western prescription medicine. The natural-extract preparations are sold as registered medications in Russia and some neighboring markets but not in Western jurisdictions. The synthetic catalog peptides are sold as research peptides through Western research-chemical vendors and as dietary peptide complexes through Russian-market channels (Peptides.ru, Khavinson Peptides product line). There are no PubMed-indexed Western randomized controlled trials of the chemically-defined catalog peptides for any specific indication, no characterized human pharmacokinetics for most entries, and no structural-biology validation of the proposed peptide-DNA binding mechanism.

For patients, the practical takeaway is that Khavinson bioregulators are a Russian-tradition peptide pharmacology with a real but modest Western-indexed peer-reviewed footprint. Anyone considering Khavinson catalog use should engage with the honest framing — these are not Western clinical medicines, the mechanistic case is interesting but not validated to mainstream molecular-biology standards, the in-vivo pharmacology is incompletely characterized in humans, and the long-term safety database is anchored in Russian clinical experience that is not well indexed in major Western databases. The catalog should not be conflated with FDA-approved peptide therapeutics, and patients with diagnosed medical conditions should not substitute Khavinson peptides for clinically validated treatments.

How members compare

Within the Khavinson catalog, the principal axis is tissue-target selectivity. The thymic/immune cluster (Vilon, Thymalin, Thymulin, Thymagen, Crystagen) overlaps with the broader Thymic Peptides family, and several members (Thymalin, Thymulin, Thymagen) appear in both. The pineal/cognitive cluster (Epitalon, Pinealon, Cortagen, n-acetyl-epitalon-amidate) is positioned for aging and cognitive support. Organ-specific entries (Cardiogen, Bronchogen, Prostamax, Testagen, Pancragen, Ovagen, Livagen, Chonluten, Vesugen, Cartalax) target their named tissues. Vilon is the most-supported in Western-indexed peer-reviewed work; Epitalon is the most-discussed in fitness and longevity communities.

Outside the Khavinson family, the closest mainstream pharmacological comparators depend on the indication. For age-related immune decline: validated approaches include vaccination (especially shingles and pneumococcal in older adults), adequate nutrition, and management of comorbidities; the Khavinson immune cluster is positioned as adjunct rather than substitute. For cognitive aging: lifestyle interventions (exercise, sleep, social engagement, hearing aids) and management of cardiovascular risk factors are evidence-supported, alongside specific medications for diagnosed conditions; the Khavinson cognitive cluster is not a substitute for these. For tissue-specific dysfunction: the relevant clinical specialties (cardiology, pulmonology, urology, etc.) have validated diagnostics and treatments that should be the foundation of care. Khavinson catalog entries should be understood as Russian-tradition adjuncts with mechanistically speculative basis, not as Western clinical medicines.

Frequently asked questions

References

• Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsOriginal Research

  Khavinson VKh, Bondarev IE, and Butyugov AA, Bulletin of Experimental Biology and Medicine 2003. The foundational paper reporting that Epitalon (KEDG) induces telomerase activity and telomere elongation in human somatic cells — the most-cited mechanistic finding for the Khavinson catalog and the basis for Epitalon's prominence in the longevity community. The result is real and peer-reviewed; the broader mechanistic interpretation has not been independently validated to Western molecular-biology standards.

• Peptide promotes overcoming of the division limit in human somatic cellOriginal Research

  Khavinson VKh and colleagues, Bulletin of Experimental Biology and Medicine 2004. The follow-up paper extending the Epitalon-telomerase work to demonstrate overcoming of the Hayflick division limit in cultured human somatic cells. Key reference for the longevity-framework discussion of the Khavinson program.

• Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathwayOriginal Research

  Khavinson VKh and colleagues, Bulletin of Experimental Biology and Medicine 2002. Reports thymocyte effects of Khavinson short peptides on blast transformation and sphingomyelin-pathway signaling — the mechanistic anchor for the immune-cluster entries (Vilon, Thymalin, Crystagen, Thymagen) and one of the more cited Khavinson mechanism papers.

• Role of peptides in epigenetic regulation of gene activities in ontogenyReview

  Khavinson VKh, Bulletin of Experimental Biology and Medicine 2012. The conceptual review articulating the Khavinson framework — short peptides as tissue-specific epigenetic regulators acting through direct DNA and chromatin interactions. The reference paper for understanding the broader mechanistic claims of the catalog.

• Transport of Biologically Active Ultrashort Peptides Using POT and LAT CarriersReview

  Khavinson V and colleagues, International Journal of Molecular Sciences 2022. Modern Khavinson-group review proposing transport mechanisms for the short peptide bioregulator catalog through proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT). Addresses the mechanistic question of how short peptides reach intracellular targets given rapid plasma degradation.

• Natural and synthetic thymic peptides as therapeutics for immune dysfunctionReview

  Morozov VG and Khavinson VKh, International Journal of Immunopharmacology 1997. The English-language review framing the natural and synthetic thymic peptide approach to immune-dysfunction therapy. One of the few extensive Western-indexed reviews from the Khavinson program.

• Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell LineOriginal Research

  Avolio F and colleagues, International Journal of Molecular Sciences 2022. Independent (non-Khavinson-group) characterization of Vilon-class peptides in monocyte/macrophage THP-1 cell line models, showing effects on proliferation and inflammatory pathways. Useful as Western-replicated mechanistic data on the immune-cluster Khavinson entries.

Related goals